XML 43 R31.htm IDEA: XBRL DOCUMENT
v3.25.3

Accrued Collaboration Credit (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Schedule of Collaborative Arrangements | The changes in these balances have been included in the table in Note 12 for reference in reconciling the Amount Billed/Submitted for Reimbursement compared to the amount of R&D Expenses Incurred.
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Beginning Balance | $ | (219,625) |  |  | $ | (201,536) |  |  | $ | (981,111) |  |  | $ | — |
Prepaid expenses included in reimbursement, not yet incurred | 10,015 |  |  | (788,934) |  |  | 424,596 |  |  | (1,238,990) |
Accrued expenses for work performed, not yet invoiced | 179,141 |  |  | (126,340) |  |  | 521,402 |  |  | 122,180 |
Foreign currency adjustments | 1,413 |  |  | (2,781) |  |  | 6,056 |  |  | (2,781) |
Ending Balance | $ | (29,057) |  |  | $ | (1,119,591) |  |  | $ | (29,057) |  |  | $ | (1,119,591) |
The table below summarizes the R&D expenses submitted for reimbursement and the R&D expenses incurred by the Company related to the collaboration, including the corresponding collaboration credits. These amounts are presented for the most recent relevant periods:
Period | Amount Billed/ Submitted for Reimbursement | Amount Reimbursed/ Received | R&D Expenses Incurred | Collaboration Credits | Variance (foreign exchange timing) | Adjustment to Deferred Collaboration Credits4 | Adjustment to Accrued Expenses5
Quarter ended March 31, 2024 | $ | 189,904 |  | $ | — |  | $ | 189,904 |  | $ | (190,553) |  | $ | (649) |  | $ | — |  | $ | — |
Quarter ended June 30, 2024 | $ | 1,341,297 |  | $ | (189,904) |  | $ | 1,139,761 |  | $ | (1,141,985) |  | $ | (2,223) |  | $ | (450,056) |  | $ | 248,520 |
Quarter ended September 30, 2024 | $ | 1,783,472 |  | $ | (1,341,297) |  | $ | 868,198 |  | $ | (867,760) |  | $ | 437 |  | $ | (788,934) |  | $ | (126,340) |
Quarter ended December 31, 2024 | $ | 601,197 |  | $ | (1,783,472) |  | $ | 739,557 |  | $ | (745,052) |  | $ | (5,495) |  | $ | 92,546 |  | $ | 45,814 |
Fiscal Year ended December 31, 2024 | $ | 3,915,870 |  | $ | (3,314,673) |  | $ | 2,937,420 |  | $ | (2,945,350) |  | $ | (7,930) |  | $ | (1,146,444) |  | $ | 167,994 |
Quarter ended March 31, 2025 | $ | 1,727,386 | 6 | $ | (990,979) | 7 | $ | 1,969,270 |  | $ | (1,966,123) |  | $ | 3,147 |  | $ | 251,304 |  | $ | (9,420) |
Quarter ended June 30, 2025 | $ | 1,168,022 |  | $ | (1,337,604) |  | $ | 1,682,980 |  | $ | (1,685,917) |  | $ | (2,937) |  | $ | 163,277 |  | $ | 351,681 |
Quarter ended September 30, 2025 | $ | 1,467,935 |  | $ | (1,422,731) |  | $ | 1,657,091 |  | $ | (1,658,248) |  | $ | (1,117) |  | $ | 10,015 |  | $ | 179,141 |
4 Change in prepaid expenses that have not yet been incurred but which have been paid/submitted for reimbursement. The Company's contract with TOI allows for reimbursement upon the Company's receipt of an allowable vendor invoice. 5 Change in expenses incurred but not billable to TOI until invoiced by a third-party vendor. 6 Includes $389,782 billed in February 2025 related to Phase 3 activities that were reimbursed by TOI prior to quarter-end March 31, 2025, plus $1,337,604 related to reimbursable first quarter 2025 R&D expenses, subsequently reimbursed in the second quarter of 2025. 7 Includes $601,197 related to fourth quarter 2024 Collaboration Receivable and $389,782 billed and reimbursed by TOI in February 2025.

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration